XML 46 R40.htm IDEA: XBRL DOCUMENT v3.25.2
Equity Method Investment - Additional Information (Details) - USD ($)
$ / shares in Units, shares in Millions
 3 Months Ended 6 Months Ended
Dec. 02, 2024
Jun. 30, 2025
Jun. 30, 2024
 [1]
Jun. 30, 2025
Jun. 30, 2024
 [1]
Dec. 31, 2024
Schedule of Equity Method Investments [Line Items]            
Equity method investment dividends or distributions       $ 20,000,000    
Equity method investment dividends or distributions per unit   $ 1        
Common Stock, Par or Stated Value Per Share   $ 0.0001   $ 0.0001   $ 0.0001
Loss from equity method investment   $ (2,386,000) $ 0 $ (6,847,000) $ 0  
Research and development expenses   29,886,000 29,724,000 60,366,000 57,132,000  
Other income   260,000 $ (36,000) 526,000 $ (135,000)  
Accrued expenses   35,099,000   35,099,000   $ 29,972,000 [2]
Accounts payable   $ 14,281,000   $ 14,281,000   $ 11,560,000 [2]
Huntsville Manufacturing Facility            
Schedule of Equity Method Investments [Line Items]            
Common unit, price per unit   $ 1   $ 1    
Percentage of the common units outstanding       100.00%    
Huntsville Manufacturing Facility | Stock Appreciation Rights (SARs)            
Schedule of Equity Method Investments [Line Items]            
Shares issued   7.6   7.6    
Shares reserved for issuance   11.3   11.3    
Gannet BioChem            
Schedule of Equity Method Investments [Line Items]            
Fair value of investment $ 12,200,000          
Loss from equity method investment   $ (2,386,000)   $ (6,847,000)    
Minimum purchase commitments   0   0    
Purchases made   0   $ 0    
Gannet BioChem | Huntsville Manufacturing Facility            
Schedule of Equity Method Investments [Line Items]            
Common units owned 20.0     20.0    
Services Agreements            
Schedule of Equity Method Investments [Line Items]            
Accrued expenses   4,600,000   $ 4,600,000    
Accounts payable   700,000   $ 700,000    
Services Agreements | Gannet BioChem            
Schedule of Equity Method Investments [Line Items]            
Agreement term       2 years    
Research and development expenses   600,000   $ 800,000    
Other income   500,000   900,000    
Net payable   $ 5,300,000   $ 5,300,000    
Asset Acquisition By Ampersand Capital Partners | Huntsville Manufacturing Facility            
Schedule of Equity Method Investments [Line Items]            
Preferred units owned by a related party       81.5    
Preferred unit, price per unit owned by related party   $ 1   $ 1    
Percentage of the preferred units owned by related party outstanding 100.00%          
Percentage of preferred units outstanding   99.70%   99.70%    
Asset Acquisition By Ampersand Capital Partners | Huntsville Manufacturing Facility | Stock Appreciation Rights (SARs)            
Schedule of Equity Method Investments [Line Items]            
Share issued base value   $ 1   $ 1    
Asset Acquisition By Ampersand Capital Partners | Asset Purchase Agreement | Huntsville Manufacturing Facility            
Schedule of Equity Method Investments [Line Items]            
Consideration in cash, net of transaction costs $ 64,700,000          
[1] All share and per share amounts have been retrospectively adjusted to reflect a one-for-fifteen reverse stock split (see Note 6).
[2] All share and per share amounts have been retrospectively adjusted to reflect a one-for-fifteen reverse stock split (see Note 6).